NCT07806838Recruiting
Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication
The Effect of Daily Mixed Spice Consumption and Protein Supplementation on Muscle Mass and Function in Adults Using GLP-1 Agonists for Weight Management: A Pilot Study
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
This pilot study will examine whether daily protein supplementation with or without a mixture of culinary spices can help preserve muscle mass and function in adults who are using GLP-1 medications for weight management. The study will include 75 adults who recently started a GLP-1 medication and are experiencing weight loss. Participants will be randomly assigned to one of three groups: standard of care, protein supplementation plus placebo capsules, or protein supplementation plus mixed spice capsules. The study will last 6 months. Researchers will compare changes in muscle mass and muscle function among the groups. Muscle mass will be measured using DEXA and D3-creatine enrichment. Muscle function will be assessed using walking, stair-climbing, and grip-strength tests. The study will also evaluate metabolic and inflammatory markers, body composition, dietary intake, physical activity, fatigue, sleep quality, quality of life, and other measures related to muscle health.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 1 Sept 2026
- Start date
- 22 Oct 2026
- Primary completion date
- 1 Sept 2028
- Lead sponsor
- University of California, Los Angeles
- Diseases
- Obesity
- NCT number
- NCT07806838
What you commit to
- Study type: Interventional
- Planned participants: 75
- From 22 Oct 2026 to the primary completion date, 1 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Eating a high-fiber/polyphenol diet or taking medication or dietary supplements that interfere with the absorption of polyphenols.
- Current use of insulin or oral medication of metformin, SU, SGLT2i, glitazone, or DPP4 as single-agent therapy or combination oral agents.
- Taking GLP-1 medications for more than 3 months.
- Have a medical implant or other metal implant, including a pacemaker.
- Unwilling to stay on a GLP-1 medication for 6 months or for the duration of study participation.
Other illness
- Allergy or sensitivity to spices, or history of allergy or anaphylaxis of any kind.
- Diagnosed with Type 2 diabetes.
- Milk protein allergy.
- Uncontrolled hypertension (systolic BP \>170 or diastolic BP \>100).
- Presence of a condition or abnormality that, in the opinion of the investigator, would compromise participant safety or data quality.
- Any unstable medical conditions or terminal diagnosis.
- Unstable thyroid disease-not taking medication or medication dosage changed one or more times over the last 6 months. Stable thyroid disease on an unchanged prescription medication dose for ≥6 months is acceptable.
Lab values
- Renal impairment measured as eGFR \<45 mL/min/1.73 m² (\<60 mL/min/1.73 m² in subjects treated with SGLT2i), according to the CKD-EPI creatinine equation as defined by KDIGO 2012.
Other
- Consume spices regularly \>5 g/day.
- Vegans/vegetarians.
- Consuming protein, amino acid, or creatine supplements; occasional or infrequent use (1 serving per week or less) is allowed.
- Severe lactose intolerance.
- Current diagnosis of alcoholism or substance addiction.
- Frequently using prebiotics, probiotics, yogurt, and/or fiber supplements.
- Pregnant, breastfeeding, or unwilling to practice birth control during study participation.
Who the study is looking for
- Male or female ≥18 years of age at screening visit.
- BMI \>27 kg/m² with weight-related conditions OR BMI \>30 kg/m².
- Taking any FDA-approved GLP-1 medication, daily oral or weekly injectable, started up to three months ago, and experiencing at least 1 lb of weight loss per week.
- Screening laboratory tests without significant abnormalities that might interfere with the study.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA Center for Human Nutrition Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.